Evidence map›Paper›PMID 40635771›Full record

ReviewInfection and drug resistance2025

Clinical Applications and Therapeutic Mechanisms of Chinese Herbal Medicine Yiaikang Capsules in Treating Acquired Immune Deficiency Syndrome.

Xue Ding, Leilei Fan, Liran Xu, Xiuxia Ma, Pengfei Meng, Jiahe Li, Jingyu Yue

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xue DingDepartment of Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
Leilei FanDepartment of Cardiovascular, The First People's Hospital of Zhengzhou, Zhengzhou, People's Republic of China.
Liran XuDepartment of the First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.ORCID 0000-0002-3992-7423
Xiuxia MaDepartment of AIDS Clinical Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
Pengfei MengDepartment of the First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
Jiahe LiDepartment of the First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
Jingyu YueDepartment of AIDS Clinical Research Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yiaikang (YAK) is a 22-component traditional herbal medicine, exhibiting a powerful inhibitory effect on viral replication and immunity-boosting activities in clinical applications, and is widely used to treat diseases in people living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) in China. In clinical studies, YAK alleviates the clinical symptoms of HIV/AIDS (eg, weakness, shortness of breath, spontaneous sweating, and diarrhea) while enhancing quality of life and improving survival rates of patients. In the molecular mechanism studies, its main therapeutic action is inhibition of HIV replication, alongside increased numbers of CD4

Indexed as

acquired immune deficiency syndromehuman immunodeficiency virusYiaikang capsule

Identifiers

PMID40635771
PMCPMC12239890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.